ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,230.99
-0.28%
Dow Jones
38,852.86
-0.55%
Gold vs US Dollar
2,345.345
-0.59%
Brent Oil
84.58
0.30%
Bitcoin
67,794.46
-0.73%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Redhill Biopharma Ltd (RDHL)

  7. Redhill Biopharma Ltd (RDHL) News

Redhill Biopharma (RDHL)

Redhill Biopharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RDHL
DateTimeSourceHeadlineSymbolCompany
06/05/202412:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
06/05/202412:00PR Newswire (US)RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035NASDAQ:RDHLRedhill Biopharma Ltd
24/04/202412:00PR Newswire (US)RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 StudyNASDAQ:RDHLRedhill Biopharma Ltd
08/04/202414:23PR Newswire (US)RedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsNASDAQ:RDHLRedhill Biopharma Ltd
02/04/202412:00PR Newswire (US)RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market PriceNASDAQ:RDHLRedhill Biopharma Ltd
11/03/202411:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
11/03/202411:00PR Newswire (US)RedHill Announces New USPTO Patent Covering Talicia® Through 2034NASDAQ:RDHLRedhill Biopharma Ltd
05/03/202412:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
05/03/202412:00PR Newswire (US)RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures ProgramsNASDAQ:RDHLRedhill Biopharma Ltd
20/02/202421:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
20/02/202412:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
20/02/202412:00PR Newswire (US)RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationNASDAQ:RDHLRedhill Biopharma Ltd
16/02/202413:54Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RDHLRedhill Biopharma Ltd
16/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RDHLRedhill Biopharma Ltd
13/02/202421:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
05/02/202413:00Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RDHLRedhill Biopharma Ltd
02/02/202421:10Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RDHLRedhill Biopharma Ltd
01/02/202415:22Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RDHLRedhill Biopharma Ltd
26/01/202417:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
26/01/202417:46PR Newswire (US)RedHill Biopharma Announces Closing of $8 Million Registered Direct OfferingNASDAQ:RDHLRedhill Biopharma Ltd
26/01/202414:31Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
26/01/202414:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RDHLRedhill Biopharma Ltd
25/01/202414:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
25/01/202414:05PR Newswire (US)RedHill Biopharma Announces $8 Million Registered Direct OfferingNASDAQ:RDHLRedhill Biopharma Ltd
25/01/202411:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
25/01/202411:00PR Newswire (US)RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042NASDAQ:RDHLRedhill Biopharma Ltd
20/12/202313:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
20/12/202313:45PR Newswire (US)RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against EbolaNASDAQ:RDHLRedhill Biopharma Ltd
12/12/202312:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
12/12/202312:00PR Newswire (US)RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:RDHLRedhill Biopharma Ltd
 Showing the most relevant articles for your search:NASDAQ:RDHL

Your Recent History

LSE
TERN
Tern
LSE
QED
Quadrise
LSE
BP.
Bp
LSE
POS
Plexus
LSE
GKP
Gulf Keystone Petroleum
LSE
GGP
Greatland Gold
LSE
AAZ
Anglo Asian Mining
LSE
AAU
Ariana Resources
LSE
BIRD
Blackbird
LSE
LLOY
Lloyds Banking
LSE
ZPHR
Zephyr Energy
LSE
NG.
National Grid
LSE
THG
Thg
LSE
SVT
Severn Trent
LSE
SCE
Surface Transforms
LSE
MATD
Petro Matad
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved